YOUR SELEON SPECIALIST

Peter Hartung
Head of BU Consulting, QM & RA, Quality Management Expert

Tel.: 07131 2774-40
regulatoryaffairs(at)seleon.de

 

Questions on this topic?

Send us a message!

 

30.11.2018

MDR legal acts – Part 1: Delegated Acts

In case of non-significant changes made to the MDR "delegated acts" are used to this effect. Using this type of legal act the EU parliament and the EU council empower the EU commission to add or amend certain aspects within the MDR/IVDR.

Change Management! The moment you realise that changes need to be made either to the quality management system or the product – we are speaking of subsequent adjustments. Up next time-consuming agreements, assessments and change requests are required ...

 

Medical device manufacturers are far from being the only ones affected by such unpleasant processes. In general the European Union, who set a huge change in motion with adopting the new MDR and the new IVDR in 2017, can add or amend the regulations subsequently – however, needs to stick to a certain set of rules in doing so. The good thing: The aspects eligible for amendments are already known. The bad thing: up to now it is entirely ambiguous to which extent and when those amendments may be made by the EU.

 

In case of non-significant changes "delegated acts" are the means of choice. This type of legal act allows for the EU Parliament and EU Council to empower the EU Commission concerning certain aspects.

 

hese delegated acts by the commission supplement or amend the MDR/IVDR with "non-significant aspects",  with the parliament and the council having the ability to withdraw the empowerment from the commission at any time or to object to the delegated act.

 

For the following aspects of the MDR the delegated acts have been enabled, allowing for non-significant changes:

  • Article 1(5): Add new product groups to Annex XVI "List of groups of products without an intended medical purpose referred to in Article 1(2)"
  • Article 3: Amend the definition of nanomaterial set out in Article 2 (18) and the related definitions in Article 2 (19), (2)0 und (21).
  • Article 10 (4): Amend Annex II "Technical Documentation" and Annex III "Technical Documentation on post-market Surveillance" in the light of technical progress.
  • Article 18 (3): Amend the list of implants exempted from fulfilling the requirements stated in Article 18 "Implant card and information to be supplied to the patient with an implanted device"
  • Article 19 (4): Amend the minimum content of the EU declaration of conformity set out in Annex IV in the light of the technical progress
  • Article 27 (10): Amend the list of information for the UDI Database and the UDI-DI set out in Annex VI Part B as well as Annex VI in the light of technical progress
  • Article 44 (10): Modify the frequency at which the complete re-assessment of the notified bodies is to be carried out.
  • Article 52 (5) Amend the list of Class IIb implants that are exempted from the Conformity Assessment Procedures laid down in Article 52.
  • Article 56 (6) Amend the minimum content of certificates set out in Annex XII "Certificates issued by a Notified Body" in the light of technical progress.
  • Article 61 (8): Amend the list of exempted Class IIb implantable devices and Class III devices defined in Article 52 (4) and 61 (6b)
  • Article 70 (8): Amend the requirements laid down in Annex XV Chapter II "Documentation regarding the Application for Clinical Investigation" in light of technical progress and global regulatory developments.
  • Article 106 (15): Amend the tasks of the expert panels and expert laboratories defined in Article 106 (10) "Provision of scientific, technical and clinical opinions and advice –  Expert panels and expert laboratories may have the following tasks, depending on the requisite needs"

 

As for every proper Change Management delegated acts are subject to procedural instructions and public databases:

  • For instance the EU commission is only empowered for a period of 5 years as of the 25th of May 2017 according to Article 115 of the MDR.
  • The commission has to inform the parliament ant the council about the content of delegated acts and they may raise objections for up to three months.

 

In general delegated acts are governed by Article 290 in the Treaty on the Functioning of the European Union

 

Adopted, delegated acts can be looked at using the search engine on the Interinstitutional register of delegated acts of the European Union.

 

What about major changes to the MDR and IVDR? The relevant regulations are dealt with within the framework of the "implementing acts".

Details can be found in the continuation of this article: MDR Legal acts Part 2: Implementing acts

 

Please note that the details and bullet points listed are not intended to be exhaustive, are supplied without liability and only serve as information.

Every product is unique – the mandatory tasks and measures for entering the market need to be specified individually. seleon advises you on your individual questions without any obligation.

CONTACT YOUR SELEON SPECIALIST

[Inhalt: Englisch]

< BACK TO OVERVIEW

 

Further entries from the "Quality management" category

Quality Management
25.07.2019

With the MDR, there are changes to many aspects of medical devices. The UDI-system is one of them and marks a turning point in the European method of traceability, as this system aims for a standardised and simple traceability. However, until the UDI-system is fully...

Quality Management
01.07.2019

Since January 1, 2019 the MDSAP-audit of your company has become mandatory for market access in Canada. Even though the other participating countries, such as the U.S., Brazil, Japan and Australia, do not have an audit obligation (yet), we cannot avoid it there. Our...

Quality Management
14.02.2019

Nothing works without software in the planning, control and implementation of medical technology projects. Tools are needed to develop efficiently and with minimal errors. But which tools are suited best?

Regulatory Affairs

Gaining approval for medical devices is complex and quite often also confusing. We bring clarity…

 

> Regulatory Affairs

Clinical Affairs

Clinical affairs of medical devices requires numerous evidences and evaluations. What we know about it …

 

> Clinical Affairs

Development Excellence

Product development of medical devices is subject to its own rules. We bring light into the darkness …

 

> Development Excellence